UAE – The Department of Health – Abu Dhabi (DoH), AbbVie Biopharmaceutical, and M42 have formed a strategic alliance to accelerate advancements in genomics and precision medicine in the Emirate.
The DoH, M42, and AbbVie will combine their complementary expertise, resources, and technology to accelerate the development of personalised medicine and genomics services for all patients.
In a press release, the DoH said: “The strategic cooperation aims to maximise on the Emirate’s unique genomics programme and translate scientific advancements into tangible patient benefits, focusing on precision medicine tailored to individual needs.”
This agreement comes after G42 and Mubadala agreed to pool resources and form a new single entity with specific strategic goals operating under the brand name M42.
Under the new strategic partnership, the DoH, M42, and AbbVie will explore collaborative opportunities to deploy precision medicine, diagnostic solutions, and innovative treatments for multiple myeloma and non-small cell lung cancer (NSCLC).
The agreement was signed by Dr. Asma Al Mannaei, Executive Director of the Research and Innovation Center at the Department of Health – Abu Dhabi, Francesco Redivo, Senior Director at G42 Healthcare, and Hala Dalle, Medical Director Gulf & Levant at AbbVie Biopharmaceutical.
Commenting on this collaboration, Dr. Asma Al Mannaei said: “Global collaboration is vital to unlocking the vast potential of personalised medicine and genomics, empowering us to revolutionise world-class and tailored healthcare for communities around the world.”
The DoH, M42, and AbbVie will also co-design, develop and drive research projects to foster the development of precision medicine and genomics in the Emirate of Abu Dhabi.
In line with the Emirate’s efforts to lead on personalised and preventive healthcare, Abu Dhabi is home to the largest genomics programme, titled The Emirati Genome Programme.
The Emirati Genome Programme aims to explore the genetic makeup of Emiratis, using cutting-edge DNA sequencing and artificial intelligence technologies to generate quality and comprehensive genomic data about Emiratis.
As the regulator of the healthcare sector in the Emirate, the DoH promises to accelerate the translation and implementation of results of upcoming research projects in the field of personalised medicine.
The Department of Health seeks to drive research, influence policy change and implementation of guidelines, which leads to broader UAE patients’ access to innovative approaches in healthcare.
“Abu Dhabi continues to harness the power of personalised medicine and genomics to unlock a new era of healthcare where every patient’s journey is guided by their own genetic blueprint, leading to enhanced quality of life and a brighter future for generations to come,” stated Dr. Asma Al Mannaei.
Moreover, the agreement will leverage Real-World Evidence (RWE) to advance care delivery and assess the effectiveness of patient support programmes and therapeutic innovations.
The DoH, M42, and AbbVie will jointly evaluate the impact of these interventions on patient outcomes and make data-driven decisions on how to improve healthcare delivery locally, regionally, and globally.
The three parties also plan to launch various initiatives that can support research and clinical trials and the development of innovative solutions to tackle health needs, challenges, and burdens
The partnership underpins the three parties’ shared goal of delivering top-notch care to patients, further cementing the Emirate’s position as a leading destination for life sciences and medical innovation.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
